Volume 43, Number 5, 200836th annual meeting of the European Radiation Research Society
|Number of page(s)||1|
|Section||Poster Presentation - New therapeutic approaches of radiation injuries|
|Published online||03 September 2008|
Meloxicam, a Cyclooxygenase-2 Inhibitor, Stimulates Myelopoiesis in Irradiated Mice Via Induction of G-CSF
Inst. Biophys., Acad. Sci. Czech Rep., Královopolská 135, 61265 Brno, Czech Republic
2 Inst. Pathophysiol., Fac. Med., Masaryk Univ., U kamenice 5, 62500 Brno, Czech Republic
Meloxicam, a non-steroidal anti-inflammatory drug acting on the principle of cyclooxygenase-2 inhibition and having an improved side-effect profile in terms of the gastrointestinal toxicity, has been found to stimulate hematopoiesis in whole-body sub-lethally or mid-lethally gamma-irradiated mice. Studies on mechanisms of the hematopoiesis-stimulating action of meloxicam have revealed elevated serum levels of granulocyte colony-stimulating factor (G-CSF) within the interval of 24 hours after the administration of the drug. Induction of production of G-CSF may be, thus, supposed to be at least partially responsible for the observed beneficial effects of meloxicam in mice with radiation-induced myelosuppression. This work was supported by the Grant Agency of the Academy of Sciences of the Czech Republic (Grant No. 1QS500040507).
Key words: meloxicam / radiation-induced myelosuppression
© EDP Sciences, 2008
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.